Natco Pharma Limited has informed the Exchange regarding a press release dated October 09, 2025, titled "Legal update regarding Risdiplam Commercial Appellate Division of the Hon ble Delhi High Court Dismissed Appeal ".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has shared a press release about a court ruling on Risdiplam, a drug used to treat Spinal Muscular Atrophy and originally sold by Roche as Evrysdi. The Commercial Appellate Division of the Delhi High Court has dismissed an appeal related to this product. The dismissal is seen as a positive outcome for Natco, as it likely clears the path for the company to proceed with its generic version of Risdiplam in India. This is significant because Risdiplam is a high-value drug globally. Investors should await further details in the full press release for clarity on the exact scope of the ruling.
Positive for Natco Pharma shareholders, as a dismissed appeal strengthens the company's position to launch a generic version of Risdiplam, potentially unlocking a new revenue stream. Stock may see positive sentiment in the short term pending further details.